MA 05.11 Endothelial Adhesion Molecule Overexpression Correlates to Decreased CD8 T Cells and Increased B/Treg Cells in Lung Cancer

BackgroundNon small cell lung cancer is one of the cancer types where Immune checkpoint blockade has demonstrated unprecedented clinical efficiency. However, only a fraction of patients benefit from such therapy; factors determining this response are yet to be elucidated. Here, we investigated whether the differentiation status of circulating CD8 T cells might be associated with outcome of PD1 blockade therapy in NSCLC.MethodsWe used multi-parameter flow cytometry to study CD8 T cell differentiation states in NSCLC patients at baseline and to examine the effects of blocking the PD1/PDL1 pathway on those cells.ResultsWe found that responders to PD1 blockade therapy has more peripheral PD1+ CD8 T cells with an early-like differentiated status at baseline and that this phenotype is associated with longer survival. Moreover, PD1 blockade induced reinvigoration is mostly observed in cells with this with an early-like differentiated status.ConclusionsAn early like differentiation status of peripheral CD8 T cells is associated with favorable outcome of PD1 blockade immunotherapy

Download Full-text

Immunostimulation During and After R-CHOP Therapy for B-Cell Lymphoma

Journal of Clinical & Experimental Immunology ◽

10.33140/jcei.01.01.07 ◽

2016 ◽

Vol 01 (01) ◽

Keyword(s):

T Cells ◽

B Cell ◽

Tumor Immunity ◽

Cd8 T Cells ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Treg Cells ◽

T Cell Subsets ◽

T Helper ◽

Chop Therapy

Backgrounds: Many studies show an immune imbalance in the tumor environment; some reports show that the T helper 1 (Th1)/ T helper 2 (Th2) ratio, the number of regulatory T-cells (Treg cells) or CD8+T-cells, and the CD8+Tcell/Treg cell ratio are associated with tumor suppression and expansion. Additionally, chemotherapy was reported to affect the immunity of patients with malignancy. Patients and Methods: Using flow cytometry we measured peripheral blood lymphocytes including non T-cells, as well as T-cell subsets such as CD3+T-cells, CD4+T-cells, CD8+T-cells, Treg cells, Th1 cells and Th2 cells before treatment, at the fourth cycle, and at 1, 3, 6 and 12 months after treatment in 21 patients with B-cell lymphoma receiving R-CHOP therapy. We also analyzed the changes in three immune indexes that reflect anti-tumor immunity (the CD4/CD8 ratio, the CD8/Treg ratio and the Th1/Th2 ratio). Results: Compared to pre-treatment there were significant decreases in the CD4/CD8 ratio between 1 month and 12 months after treatment (p<0.001, for all time points). The CD8/Treg ratio gradually increased with treatment with significant increases observed at 6 months (p=0.009) and 12 months after treatment (p=0.002). The Th1/ Th2 ratio showed a significant increase only before 4 cycles of therapy (p=0.007). Conclusion: Based on the changes in these three immune indexes, we propose that anti-tumor immunity improved after R-CHOP therapy, which enhanced the efficacy of R-CHOP therapy for lymphoma as well as its direct cytotoxic activity

Download Full-text

Variance of TNFAIP8 expression between tumor tissues and tumor-infiltrating CD4+ and CD8+ T cells in non-small cell lung cancer

Tumor Biology ◽

10.1007/s13277-013-1307-9 ◽

2013 ◽

Vol 35 (3) ◽

pp. 2319-2325 ◽

Cited By ~ 15

Author(s):

Lingcheng Wang ◽

Yinghua Song ◽

Xuelin Men

Keyword(s):

Lung Cancer ◽

T Cells ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cd8 T Cells ◽

Small Cell ◽

Small Cell Lung ◽

Tumor Tissues

Download Full-text

Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8+ T Cells in Non-small Cell Lung Cancer

Frontiers in Oncology ◽

10.3389/fonc.2018.00631 ◽

2018 ◽

Vol 8 ◽

Cited By ~ 9

Author(s):

Jin Ye ◽

Man-Man Zou ◽

Pei Li ◽

Xi-Jun Lin ◽

Qi-Wei Jiang ◽

...

Keyword(s):

Lung Cancer ◽

T Cells ◽

Small Cell Lung Cancer ◽

Tumor Immunity ◽

Cell Lung Cancer ◽

Cd8 T Cells ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer

Cellular Physiology and Biochemistry ◽

10.1159/000491615 ◽

2018 ◽

Vol 47 (6) ◽

pp. 2407-2419 ◽

Cited By ~ 13

Author(s):

Hong-Min Wang ◽

Xiao-Hong Zhang ◽

Ming-Ming Feng ◽

Yan-Jun Qiao ◽

Li-Qun Ye ◽

...

Keyword(s):

Lung Cancer ◽

T Cells ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cd8 T Cells ◽

Peripheral Blood ◽

Cd4 T Cells ◽

Small Cell ◽

Small Cell Lung ◽

Nsclc Patients

Background/Aims: Interleukin (IL)-35 has immunosuppressive functions in autoimmune diseases, infectious diseases, and certain cancers. However, few studies have focused on its immunoregulatory activity in non-small cell lung cancer (NSCLC). Thus, we investigated the role of IL-35 in the pathogenesis of this disease. Methods: A total of 66 NSCLC patients and 21 healthy individuals were enrolled. IL-35 expression in peripheral blood and bronchoalveolar lavage fluid (BALF) was measured. The modulatory functions of IL-35 on purified CD4+ and CD8+ T cells from NSCLC patients were investigated in direct and indirect coculture systems with NSCLC cell lines. Results: IL-35 expression was significantly increased in BALF from the tumor site, but not in the peripheral blood of NSCLC patients. IL-35 did not affect the bioactivity including proliferation, cytokine production, cell cycle, and cellular invasion of NSCLC cells. It suppressed responses from type 1 T helper (Th1) and Th17 cells but elevated the regulatory T cell response in cultured CD4+ T cells from NSCLC patients, and reduced cytokine-mediated CD4+ T cells cytotoxicity to NSCLC cells. Moreover, IL-35 also inhibited cytotoxic gene expression in CD8+ T cells from NSCLC, reducing their cytolytic and noncytolytic functions. Conclusion: The results of this study suggest that IL-35 contributes to the dysfunction/exhaustion of T cells and limited antitumor immune responses in NSCLC.

Download Full-text

CD8+ T Cells Form the Predominant Subset of NKG2A+ Cells in Human Lung Cancer

Frontiers in Immunology ◽

10.3389/fimmu.2019.03002 ◽

2020 ◽

Vol 10 ◽

Author(s):

Yongyuan Chen ◽

Zhongwei Xin ◽

Lijian Huang ◽

Lufeng Zhao ◽

Shijie Wang ◽

...

Keyword(s):

Lung Cancer ◽

T Cells ◽

Cd8 T Cells ◽

Human Lung ◽

Human Lung Cancer

Download Full-text

CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target

Cancer Cell International ◽

10.1186/s12935-019-0969-9 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Ayobami Matthew Olajuyin ◽

Adefunke Kafayat Olajuyin ◽

Ziqi Wang ◽

Xingru Zhao ◽

Xiaoju Zhang

Keyword(s):

Lung Cancer ◽

T Cells ◽

Endothelial Cells ◽

Cell Adhesion ◽

Adhesion Molecule ◽

Therapeutic Target ◽

Cell Adhesion Molecule ◽

Calotropis Procera ◽

Clinical Implications ◽

Cd146 Expression

Abstract CD146 alternatively called melanoma cell adhesion molecule (MCAM), is a biomarker and therapeutic target of clinical significance. It is found on different cells including the endothelial cells and lymphocytes which participate in heterotypic and homotypic ligand-receptor. This review concentrated on the CD146 expression T cells (or lymphocytes) centering on Treg in lung cancer. Here, we have also considered the vigorous investigation of CD146 mainly acknowledged new roles, essential mechanisms and clinical implications of CD146 in cancer. CD146 has progressively become a significant molecule, particularly recognized as a novel biomarker, prognosis and therapy for cancer. Hence, targeting CD146 expression by utilization of methanol extracts of Calotropis procera leaf may be useful for the treatment of carcinogenesis.

Download Full-text